These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29025600)

  • 1. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.
    Sadras T; Heatley SL; Kok CH; McClure BJ; Yeung D; Hughes TP; Sutton R; Ziegler DS; White DL
    Cancer Genet; 2017 Oct; 216-217():86-90. PubMed ID: 29025600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
    Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
    Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
    Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
    Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
    Malinge S; Ben-Abdelali R; Settegrana C; Radford-Weiss I; Debre M; Beldjord K; Macintyre EA; Villeval JL; Vainchenker W; Berger R; Bernard OA; Delabesse E; Penard-Lacronique V
    Blood; 2007 Mar; 109(5):2202-4. PubMed ID: 17068151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research advances in the role of JAK2 mutations in acute leukemia].
    Zhang HY; Zhai XW
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
    Wu SC; Li LS; Kopp N; Montero J; Chapuy B; Yoda A; Christie AL; Liu H; Christodoulou A; van Bodegom D; van der Zwet J; Layer JV; Tivey T; Lane AA; Ryan JA; Ng SY; DeAngelo DJ; Stone RM; Steensma D; Wadleigh M; Harris M; Mandon E; Ebel N; Andraos R; Romanet V; Dölemeyer A; Sterker D; Zender M; Rodig SJ; Murakami M; Hofmann F; Kuo F; Eck MJ; Silverman LB; Sallan SE; Letai A; Baffert F; Vangrevelinghe E; Radimerski T; Gaul C; Weinstock DM
    Cancer Cell; 2015 Jul; 28(1):29-41. PubMed ID: 26175414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
    Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
    Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
    Mullighan CG
    Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
    Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
    Kearney L; Gonzalez De Castro D; Yeung J; Procter J; Horsley SW; Eguchi-Ishimae M; Bateman CM; Anderson K; Chaplin T; Young BD; Harrison CJ; Kempski H; So CW; Ford AM; Greaves M
    Blood; 2009 Jan; 113(3):646-8. PubMed ID: 18927438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
    Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
    Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
    Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
    Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
    Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
    Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
    Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.
    Van Roosbroeck K; Cox L; Tousseyn T; Lahortiga I; Gielen O; Cauwelier B; De Paepe P; Verhoef G; Marynen P; Vandenberghe P; De Wolf-Peeters C; Cools J; Wlodarska I
    Blood; 2011 Apr; 117(15):4056-64. PubMed ID: 21325169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.
    Roncero AM; López-Nieva P; Cobos-Fernández MA; Villa-Morales M; González-Sánchez L; López-Lorenzo JL; Llamas P; Ayuso C; Rodríguez-Pinilla SM; Arriba MC; Piris MA; Fernández-Navarro P; Fernández AF; Fraga MF; Santos J; Fernández-Piqueras J
    Leukemia; 2016 Jan; 30(1):94-103. PubMed ID: 26216197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
    Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
    Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
    Kucine N; Marubayashi S; Bhagwat N; Papalexi E; Koppikar P; Sanchez Martin M; Dong L; Tallman MS; Paietta E; Wang K; He J; Lipson D; Stephens P; Miller V; Rowe JM; Teruya-Feldstein J; Mullighan CG; Ferrando AA; Krivtsov A; Armstrong S; Leung L; Ochiana SO; Chiosis G; Levine RL; Kleppe M
    Blood; 2015 Nov; 126(22):2479-83. PubMed ID: 26443624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.